(Q55485379)

12 July 2018

title

The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study. (English)

1 reference

12 July 2018

author name string

C M Carapella

1

1 reference

12 July 2018

M G Paggi

2

1 reference

12 July 2018

F Cattani

3

1 reference

12 July 2018

G B Ciottoli

4

1 reference

12 July 2018

A Floridi

5

1 reference

12 July 2018

B Iandolo

6

1 reference

12 July 2018

L Raus

7

1 reference

12 July 2018

A Riccio

8

1 reference

12 July 2018

A Caputo

9

1 reference

12 July 2018

publication date

1 May 1989

1 reference

12 July 2018

Journal of Neuro-Oncology

published in

1 reference

12 July 2018

volume

7

1 reference

12 July 2018

issue

1

1 reference

12 July 2018

page(s)

103-108

1 reference

12 July 2018

https://scigraph.springernature.com/pub.10.1007/bf00149384

exact match

0 references

cites work

Treatment of adult malignant gliomas

1 reference

12 December 2020

Preliminary Results in some Tumor Systems with Indazolecarboxylic Acids

1 reference

12 December 2020

Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma

1 reference

12 December 2020

Phase I and clinical pharmacologic evaluation of Lonidamine in patients with advanced cancer

1 reference

12 December 2020

Inhibition of the recovery from potentially lethal damage by lonidamine

1 reference

12 December 2020

Correlation of Experimental and Clinical Studies of Metabolism by PET Scanning

1 reference

12 December 2020

Early observations on the administration of Lonidamine in cancer patients

1 reference

12 December 2020

Phase I toxicologic study of Lonidamine in cancer patients

1 reference

12 December 2020

Combined modality treatment of malignant glioma

1 reference

12 December 2020

Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells

1 reference

12 December 2020

Regulation of hexokinase in cultured gliomas.

1 reference

12 December 2020

Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography.

1 reference

12 December 2020

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

1 reference

12 December 2020

Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors

1 reference

12 December 2020

Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study

1 reference

12 December 2020

Lonidamine in primary malignant brain tumors. Preliminary report.

1 reference

12 December 2020

CCNU-chemotherapy of hemispheric supratentorial glioblastoma multiforme

1 reference

12 December 2020

Phase II evaluation of Lonidamine in patients with advanced malignancy

1 reference

12 December 2020

The Metabolism of the Glioblastoma: Pathobiological Correlates

1 reference

12 December 2020

Effect of lonidamine on the utilization of 14C-labeled glucose by human astrocytoma cells

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

Effect of lonidamine on human malignant gliomas: biochemical studies

1 reference

12 December 2020

Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells

1 reference

12 December 2020

Potentiation of radiation effects on two murine tumors by lonidamine

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00149384

1 reference

12 July 2018

Dimensions Publication ID

1016458611

0 references

1 reference

12 July 2018